Skip to main content
Terug
Watch Compare

Evommune, Inc.

Datakwaliteit: 100%
EVMN
NYSE Manufacturing Chemicals
€ 26,04
▲ € 0,53 (2,08%)
Marktkapitalisatie: 1,02 B
Prijs
€ 28,30
Marktkapitalisatie
1,02 B
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -76,68 M
Capital efficient — spends only 1,81% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-33,50%
Boven sectorgemiddelde (-54,47%)
ROIC-30,93%
Net Margin-529,77%
Op. Margin-623,62%

Veiligheid

Debt / Equity
N/A
Current Ratio7,87
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-14,80 | -7,60
Onder sectorgemiddelde (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -14,8 -1,5
P/B — 1,6
ROE % -33,5 -54,5
Net Margin % -529,8 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

7 analisten
Buy
Huidig
€ 26,04
+95.9%
Koersdoel
€ 51,00
€ 48,00
€ 50,00
€ 55,00
Vooruitzicht
Forward K/W -7,60
Forward WPA -€ 3,36
Omzet Sch. 878.860,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 3,36
-€ 4,16 – -€ 2,60
 878.860,0 7
FY2026 -€ 3,21
-€ 6,22 – -€ 2,25
 6,11 M 8

Winstverassingen

Laatste 2 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,84 -€ 1,43 -69,8%
Q32025 -€ 11,36 -€ 8,07 +28,9%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 13,00 M Net Income (TTM) -68,87 M
ROE -33,50% ROA -30,62%
Gross Margin N/A Operating Margin -623,62%
Net Margin -529,77% Free Cash Flow (TTM) -76,68 M
ROIC -30,93% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 7,87
Interest Coverage N/A Asset Turnover 0,06
Working Capital 71,53 M Tangible Book Value -183,14 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -14,80 Forward P/E -7,60
P/B Ratio N/A P/S Ratio 78,41
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 1159,82 Fwd Earnings Yield N/A
FCF Yield -7,52%
Market Cap 1,02 B Enterprise Value 992,51 M
Per Share
EPS (Diluted TTM) -11,22 Revenue / Share 0,36
FCF / Share -2,13 OCF / Share -2,12
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,81% FCF Conversion 111,33%
SBC-Adj. FCF -82,53 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025
Revenue 13,00 M
Net Income -68,87 M
EPS (Diluted) -11,22
Gross Profit —
Operating Income -81,07 M
EBITDA —
R&D Expenses 74,04 M
SG&A Expenses —
D&A 600.000,0
Interest Expense —
Income Tax 0,0

Balance Sheet

Annual, most recent first
Metric FY2025
Total Assets 224,95 M
Total Liabilities 19,38 M
Shareholders' Equity 205,57 M
Total Debt —
Cash & Equivalents 44,06 M
Current Assets 153,48 M
Current Liabilities 17,91 M